Explore as Antithrombotic Therapy Advances (2025)
Cardiovascular research in 2025 has further refined antithrombotic management in acute coronary syndromes (ACS), atrial fibrillation (AF), and prosthetic valve disease, with a strong emphasis on individualized risk assessment and bleeding reduction. In ACS, the TARGET-FIRST trial showed that stopping aspirin after one month of dual antiplatelet therapy (DAPT) and continuing potent P2Y12 inhibitor monotherapy…